The development of ABL tyrosine kinase inhibitors that were originated against the oncogenic BCR-ABL protein for the treatment of chronic myeloid leukemia (CML) is the most successful example of molecular targeted therapy to date. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.